We’re excited to introduce our latest application note: “Retention Time Prediction and Intact Mass Validation Improves Automated Antibody Sequencing in PEAKS AB 3.5.” This publication showcases how PEAKS AB continues to evolve as a leading software platform for de novo antibody sequencing, now enhanced with powerful features for greater accuracy and automation.

In this update, we’ve implemented retention time (RT) prediction and intact mass deconvolution to tackle longstanding challenges in monoclonal antibody sequencing—like isobaric residue differentiation and CDR misassignments. Users can now confidently validate assembled sequences against intact mass data and minimize manual edits, all within an intuitive interface.

The note also highlights in-depth glycan profiling, I/L differentiation, and full support for timsTOF data, reinforcing PEAKS AB 3.5 as a comprehensive solution for therapeutic antibody characterization.

Whether you’re working in therapeutic development, biosimilar design, or antibody engineering, this application note demonstrates how PEAKS AB 3.5 can streamline your workflow and deliver more reliable results.

Contact us at sales@bioinfor.com to learn how PEAKS AB 3.5 can support your research.